Abstract
Beta-blocker therapy is accepted to reduce perioperative cardiovascular complications. Moreover, betablockers have potentially beneficial effects other than prevention of cardiac events. In addition to reducing anesthetic and analgesic requirements during the perioperative period, beta-blockers have neuroprotective effects, possible effectiveness in the management of intraoperative awareness-induced post-traumatic stress disorder, and antinociceptive effects. Betablockers are also useful in stabilizing hemodynamics during electroconvulsive therapy, intubation and emergency periods. Physicians need to bear in mind the benefits of beta-blockers for purposes other than preventing cardiac events when applied in the perioperative period, and should be familiar with the pharmacodynamics and effective dosages of these agents.
Current Drug Targets
Title: Beta-blockers in the Perioperative Period: Are there Indications other than Prevention of Cardiac Ischemia?
Volume: 10 Issue: 9
Author(s): Y. Kadoi and S. Saito
Affiliation:
Abstract: Beta-blocker therapy is accepted to reduce perioperative cardiovascular complications. Moreover, betablockers have potentially beneficial effects other than prevention of cardiac events. In addition to reducing anesthetic and analgesic requirements during the perioperative period, beta-blockers have neuroprotective effects, possible effectiveness in the management of intraoperative awareness-induced post-traumatic stress disorder, and antinociceptive effects. Betablockers are also useful in stabilizing hemodynamics during electroconvulsive therapy, intubation and emergency periods. Physicians need to bear in mind the benefits of beta-blockers for purposes other than preventing cardiac events when applied in the perioperative period, and should be familiar with the pharmacodynamics and effective dosages of these agents.
Export Options
About this article
Cite this article as:
Kadoi Y. and Saito S., Beta-blockers in the Perioperative Period: Are there Indications other than Prevention of Cardiac Ischemia?, Current Drug Targets 2009; 10 (9) . https://dx.doi.org/10.2174/138945009789108800
DOI https://dx.doi.org/10.2174/138945009789108800 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Concerns and Hopes for Stem Cell Therapy in Cardiology: Focus on Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry Implication of Gut Microbiota in Human Health
CNS & Neurological Disorders - Drug Targets Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs)
Current Vascular Pharmacology Study of Prolactin Permeation Through the Pericardium and Its Bioavailability
Protein & Peptide Letters The Effects of Obesity on Drug Metabolism in Children
Drug Metabolism Letters Use of Social Media at Cardiovascular Congresses: Opportunities for Education and Dissemination
Current Cardiology Reviews Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19
Combinatorial Chemistry & High Throughput Screening Persistence of Trypanosoma cruzi in Experimental Chagasic Cardiomyopathy
Anti-Infective Agents The Neuroprotective Effect of Ginkgo biloba Leaf Extract and its Possible Mechanism
Central Nervous System Agents in Medicinal Chemistry Molecular Mechanisms of Neuronal Histamine and its Receptors in Obesity
Current Molecular Pharmacology HDL Dysfunction Caused by Mutations in apoA-I and Other Genes that are Critical for HDL Biogenesis and Remodeling
Current Medicinal Chemistry Modulation of Inflammatory Response Improves Myocardial Infarct Healing in Rats
Current Pharmaceutical Design Nanomedicine: Magnetic Nanoparticles and their Biomedical Applications
Current Medicinal Chemistry Gadolinium-Deferasirox-D-Glucosamine: Novel Anti-Tumor and MR Molecular (Theranostic) Imaging Agent
Current Radiopharmaceuticals The Effect of Antihypertensive Drugs on Central Blood Pressure Beyond Peripheral Blood Pressure. Part I: (Patho)-Physiology, Rationale and Perspective on Pulse Pressure Amplification
Current Pharmaceutical Design Relationships of Birthweight and Postnatal Growth with Metabolic Risk Factors in Junior School Children in Korea
Current Hypertension Reviews Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design Meet Our Associate Editor
Current Cardiology Reviews